Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post Hoc Analyses of Two Phase 3 Trials

Jeffrey R. Curtis,Atul Deodhar,Enrique R. Soriano,Emmanouil Rampakakis,May Shawi, Natalie J. Shiff, Chenglong Han,William Tillett,Dafna D. Gladman

Rheumatology and Therapy（2024）

引用 0|浏览1

暂无评分

摘要

Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic arthritis (PsA). Post hoc analyses evaluated 1120 patients with PsA receiving guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo from DISCOVER-1 (31

查看译文

关键词

Disease activity,Fatigue,Guselkumab,Joint disease,Minimal clinically meaningful improvement,Pain,Patient-reported outcome,Physical function,Psoriatic arthritis,Skin psoriasis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要